Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GEMP Gemphire Therapeutics	$0.64	$4.97	$0.24 ▼ $1.49	$9.52M	2.82	127,174 shs	23,998 shs
HILS Hillstream BioPharma	$1.35 +2.3%	$1.52	$0.19 ▼ $2.65	$23.76M	3.08	1.39 million shs	23,627 shs
NNVC NanoViricides	$1.50 +2.0%	$1.51	$0.94 ▼ $2.34	$24.11M	0.96	244,988 shs	119,872 shs
TAOX Synaptogenix	$8.40 -8.6%	$0.00	$1.84 ▼ $11.98	$11.67M	1.87	302,908 shs	249,502 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GEMP Gemphire Therapeutics	0.00%	+1.60%	-5.00%	-6.50%	-83.07%
HILS Hillstream BioPharma	+2.27%	+9.40%	-17.18%	+1.50%	-53.92%
NNVC NanoViricides	0.00%	-5.06%	-8.54%	+6.38%	-21.47%
TAOX Synaptogenix	0.00%	+36.36%	+839,999,900.00%	+839,999,900.00%	+839,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	0.3099 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.0
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
GEMP Gemphire Therapeutics	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	$0.54 per share	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GEMP Gemphire Therapeutics	-$23.64M	N/A	0.00	∞	N/A	N/A	-419.70%	-173.05%	N/A
HILS Hillstream BioPharma	-$8.47M	-$0.72	N/A	N/A	N/A	N/A	-188.44%	-149.61%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A

Latest GEMP, NNVC, HILS, and TAOX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GEMP Gemphire Therapeutics	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GEMP Gemphire Therapeutics	N/A	0.67	0.67
HILS Hillstream BioPharma	N/A	3.01	3.01
NNVC NanoViricides	N/A	3.44	2.47
TAOX Synaptogenix	N/A	72.59	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GEMP Gemphire Therapeutics	17.53%
HILS Hillstream BioPharma	13.36%
NNVC NanoViricides	10.30%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
GEMP Gemphire Therapeutics	22.70%
HILS Hillstream BioPharma	30.24%
NNVC NanoViricides	4.60%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GEMP Gemphire Therapeutics	9	14.87 million	N/A	Not Optionable
HILS Hillstream BioPharma	1	17.60 million	12.28 million	Not Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A

GEMP, NNVC, HILS, and TAOX Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GEMP, NNVC, HILS, and TAOX Company Descriptions

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Hillstream BioPharma NASDAQ:HILS

$1.35 +0.03 (+2.27%)

As of 08/15/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

NanoViricides NYSE:NNVC

$1.50 +0.03 (+2.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.33%)

As of 08/15/2025 07:35 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Synaptogenix NASDAQ:TAOX

$8.40 -0.79 (-8.60%)

As of 08/15/2025 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time